跳至主要内容
临床试验/ACTRN12622000367741
ACTRN12622000367741招募中未知

The efficacy of foot immersion alone or combined with fan use and skin wetting as a low-cost cooling strategy for older adults during hot humid and hot dry heatwaves

The University of Sydney0 个研究点目标入组 41 人开始时间: 2022年3月2日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
41

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
60 Years 至 o limit(—)
性别
All

入选标准

  • Healthy Cohort (The University of Sydney, Sydney AU):
  • - 60+ years
  • - Non-smoker or ex-smoker (quit greater than 2 y prior)
  • - Otherwise healthy
  • - No difficult understanding or speaking English
  • CAD Cohort (Montreal Heart Institute, Montreal CA):
  • -Age between 50 and 80 years.
  • -History of angiographic coronary artery disease (greater than or equal to 70% arterial diameter narrowing of at least one major epicardial coronary artery) and/or prior coronary revascularization and/or documented prior acute coronary syndrome and/or stable angina and/or perfusion defect during exercise or pharmacological stress testing.

排除标准

  • Healthy Cohort (The University of Sydney, Sydney AU):
  • -Body mass index greater than or equal to 40 kg/m2.
  • -Hormonal replacement therapy.
  • -Uncontrolled hypertension (greater than 180/110 mmHg).
  • -Uncontrolled diabetes or severe complications of diabetes.
  • -Evidence of severe renal disease, liver disease, cerebrovascular disease, pulmonary disease, endocrine abnormalities, cognitive impairment, psychiatric disorder, substance abuse, degenerative neurological condition or any other medical condition deemed to pose risk during the study visits.
  • -Medication known to cause hyper- or hypo-hidrosis (except those taken for hypertension).
  • -Currently taking a beta-blocker.
  • -Evidence of current fluid and electrolyte disorders
  • -Current diagnosis of anemia
  • -Abnormal thyroid function
  • -Arrhythmias at rest or during cardiac stress test
  • -Significant cognitive impairment, psychiatric disorder, substance abuse, degenerative neurological condition
  • -Any other medical condition deemed to pose risk during the proposed testing or experiments, or preclude them from completing the screening stress test.
  • CAD Cohort (Montreal Heart Institute, Montreal, CA):
  • -CAD-related hospitalisation or changes in cardiac medications or change in pattern of angina less than 3 months prior to enrolment.
  • -Body mass index greater than or equal to 40 kg/m2.
  • -Hormonal replacement therapy (less than 1 year) for female participants.
  • -Uncontrolled hypertension (greater than 180/110 mmHg).
  • -Uncontrolled diabetes or severe complications of diabetes.
  • -Recent (less than 3 months) coronary bypass surgery.
  • -Ejection fraction less than 40% and/or clinical evidence/history of heart failure.
  • -Significant valve heart disease.
  • -Resting ECG abnormalities interfering with observation of ST segment changes during testing.
  • -Evidence of severe renal disease, liver disease, cerebrovascular disease, pulmonary disease, endocrine abnormalities, cognitive impairment, psychiatric disorder, substance abuse, degenerative neurological condition or any other medical condition deemed to pose risk during the study visits.

研究者

相似试验